Wyeth Ceases Production of its Injectable Influenza Vaccine and Pneumococcal Polysaccharide Vaccine

MADISON N.J. -- Wyeth has announced it is ceasing production of two of its vaccine products -- FluShield, an injectable influenza virus vaccine and Pnu-Imune, an injectable polysaccharide pneumococcal vaccine for adults. Adequate supplies of injectable flu vaccine are now available in the U.S. as a result of recent capacity increases provided by other manufacturers.

In addition, Wyeth has chosen to pursue new flu immunization technologies - specifically through its partnership with MedImmune to develop and market FluMist, an intranasal influenza vaccine. The focus on developing new vaccine products should result in better choices for physicians and patients, but requires a reallocation of company resources.

Wyeth is making this announcement now, well in advance of the 2003-2004 season, to give those companies remaining in the marketplace sufficient time to prepare and produce vaccine for the next season.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.